Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1,424 Mln
Revenue (TTM)
$788 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.2 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
1.4
Industry P/E
27.93
EV/EBITDA
-21.4
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
355,107,008
CFO
€692.51 Mln
EBITDA
€626.20 Mln
Net Profit
€145.79 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Evotec SE ADR (EVO)
| 13.9 | 19.3 | 6.7 | -8.4 | -29.3 | -18.1 | 8.0 |
|
BSE Sensex
| 4.4 | 2.7 | 8.5 | 10.1 | 14.6 | 21.7 | 11.3 |
|
Company
|
2024
|
2023
|
|---|---|---|
|
Evotec SE ADR (EVO)
| -64.2 | 45.0 |
|
BSE Sensex
| 8.1 | 18.7 |
|
BSE Sensex
| 8.1 | 18.7 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. It operates in two segments, Shared R&D and Just Evotec Biologics. The company is developing pharmaceutical products in various... therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, fibrosis, immunology, pain and inflammation, infectious, kidney, liver, rare, respiratory, fibrotic and metabolic disease; central nervous system (CNS) and cardio metabolic disorders; and animal and women health. The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore. It also has a partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB; Bayer, Novo Nordisk, Eli Lilly, and Novartis company for kidney disease; and Sandoz, patient advocacy groups, and venture capital, as well as a strategic research collaboration agreement with Bristol Myers Squibb to build a molecular glue based pipeline for unmet medical needs. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany. Address: Essener Bogen 7, Hamburg, Germany, 22419 Read more
Interim CEO, Member of the Management Board & Member of the Supervisory Board
Dr. Mario Polywka DPHIL, Ph.D.
Interim CEO, Member of the Management Board & Member of the Supervisory Board
Dr. Mario Polywka DPHIL, Ph.D.
Headquarters
Hamburg
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Evotec SE ADR (EVO) stood at $ 2,302 Mln as on 31-Mar-25
The share price of Evotec SE ADR (EVO) is $4.74 (NASDAQ) as of 23-May-2025 12:44 EDT. Evotec SE ADR (EVO) has given a return of -29.32% in the last 3 years.
Evotec SE ADR (EVO) has a market capitalisation of $ 1,424 Mln as on 22-May-2025. As per Value Research classification, it is a company.
The P/B ratio of Evotec SE ADR (EVO) is 1.42 times as on 22-May-2025, a 70% discount to its peers’ median range of 4.70 times.
Since, TTM earnings of Evotec SE ADR (EVO) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Evotec SE ADR (EVO) and enter the required number of quantities and click on buy to purchase the shares of Evotec SE ADR (EVO).
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. It operates in two segments, Shared R&D and Just Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, fibrosis, immunology, pain and inflammation, infectious, kidney, liver, rare, respiratory, fibrotic and metabolic disease; central nervous system (CNS) and cardio metabolic disorders; and animal and women health. The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore. It also has a partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB; Bayer, Novo Nordisk, Eli Lilly, and Novartis company for kidney disease; and Sandoz, patient advocacy groups, and venture capital, as well as a strategic research collaboration agreement with Bristol Myers Squibb to build a molecular glue based pipeline for unmet medical needs. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany. Address: Essener Bogen 7, Hamburg, Germany, 22419
The CEO & director of Dr. Mario Polywka DPHIL, Ph.D.. is Evotec SE ADR (EVO), and CFO & Sr. VP is Dr. Mario Polywka DPHIL, Ph.D..
There is no promoter pledging in Evotec SE ADR (EVO).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| Evotec SE ADR (EVO) | Ratios |
|---|---|
|
Return on equity(%)
|
-22.01
|
|
Operating margin(%)
|
-17.42
|
|
Net Margin(%)
|
-26.26
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Evotec SE ADR (EVO) was $0 Mln.
$0.71
(
